The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy.

[1]  I. Longini,et al.  Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness. , 2017, Vaccine.

[2]  Denicar Lina Nascimento Fabris Maeda,et al.  Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein , 2017, Front. Immunol..

[3]  E. Harris,et al.  Immune correlates of protection for dengue: State of the art and research agenda. , 2017, Vaccine.

[4]  J. Deen.  The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits , 2016, PLoS medicine.

[5]  A. Rothman,et al.  Dengue Vaccine: The Need, the Challenges, and Progress. , 2016, The Journal of infectious diseases.

[6]  Simon I Hay,et al.  The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. , 2016, The Lancet. Infectious diseases.

[7]  David L. Smith,et al.  Quantifying the Epidemiological Impact of Vector Control on Dengue , 2016, PLoS neglected tropical diseases.

[8]  D. Cummings,et al.  Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection. , 2016, The Journal of infectious diseases.

[9]  S. Halstead,et al.  Protective and immunological behavior of chimeric yellow fever dengue vaccine. , 2016, Vaccine.

[10]  B. Guy,et al.  Vaccination Against Dengue: Challenges and Current Developments. , 2016, Annual review of medicine.

[11]  E. Harris,et al.  Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort , 2016, Proceedings of the National Academy of Sciences.

[12]  B. Guy,et al.  Dengue vaccine: hypotheses to understand CYD-TDV-induced protection , 2015, Nature Reviews Microbiology.

[13]  Nicholas Jackson,et al.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. , 2015, The New England journal of medicine.

[14]  G. Carrasquilla,et al.  Efficacy of a tetravalent dengue vaccine in children in Latin America. , 2015, The New England journal of medicine.

[15]  P. Pitisuttithum,et al.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial , 2014, The Lancet.

[16]  Bhumi P. Patel,et al.  Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera , 2014, PLoS pathogens.

[17]  Stephen J. Thomas.  Developing a dengue vaccine: progress and future challenges , 2014, Annals of the New York Academy of Sciences.

[18]  T. Endy,et al.  Dengue human infection model performance parameters. , 2014, The Journal of infectious diseases.

[19]  Derek A T Cummings,et al.  A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. , 2014, The Journal of infectious diseases.

[20]  Stephen J. Thomas,et al.  Current issues in dengue vaccination , 2013, Current opinion in infectious diseases.

[21]  E. Harris,et al.  Symptomatic Versus Inapparent Outcome in Repeat Dengue Virus Infections Is Influenced by the Time Interval between Infections and Study Year , 2013, PLoS neglected tropical diseases.

[22]  Madison,et al.  Surveillance for travel-related disease--GeoSentinel Surveillance System, United States, 1997-2011. , 2013, Morbidity and mortality weekly report. Surveillance summaries.

[23]  T. Wartel,et al.  Challenges in the clinical development of a dengue vaccine. , 2013, Current opinion in virology.

[24]  Stephen J. Thomas.  Dengue human infection model , 2013, Human vaccines & immunotherapeutics.

[25]  A. Durbin,et al.  The dengue human challenge model: has the time come to accept this challenge? , 2013, The Journal of infectious diseases.

[26]  Jessica R. Fried,et al.  Dengue and US Military Operations from the Spanish–American War through Today , 2012, Emerging infectious diseases.

[27]  Stephen J. Thomas,et al.  Critical issues in dengue vaccine development , 2011, Current opinion in infectious diseases.

[28]  R. Edelman,et al.  Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. , 2011, The Journal of infectious diseases.

[29]  A. Nisalak,et al.  Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance. , 2009, The American journal of tropical medicine and hygiene.

[30]  M. Accavitti-Loper,et al.  Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. , 2009, Virology.

[31]  S. Plotkin,et al.  Vaccines: correlates of vaccine-induced immunity. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  A. Barrett,et al.  Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17-18 November 2005. , 2007, Vaccine.

[33]  M. Deem,et al.  Sculpting the immunological response to dengue fever by polytopic vaccination. , 2006, Vaccine.

[34]  F. Guirakhoo,et al.  Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All , 2006, Human vaccines.

[35]  J. Morvan,et al.  Use of Four Dengue Virus Antigens for Determination of Dengue Immune Status by Enzyme-Linked Immunosorbent Assay of Immunoglobulin G Avidity , 2005, Journal of Clinical Microbiology.

[36]  Alan L Rothman,et al.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. , 2004, The Journal of infectious diseases.

[37]  F. Guirakhoo,et al.  Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. , 2002, Virology.

[38]  Susana Vázquez,et al.  Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. , 2002, Revista panamericana de salud publica = Pan American journal of public health.

[39]  J. Lang,et al.  Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. , 2002, The American journal of tropical medicine and hygiene.

[40]  S. Halstead,et al.  Epidemiologic studies on Dengue in Santiago de Cuba, 1997. , 2000, American journal of epidemiology.

[41]  R. Haas.  [Oral immunization against poliomyelitis]. , 1973, Deutsche medizinische Wochenschrift.

[42]  A. Sabin.  Recent advances in our knowledge of dengue and sandfly fever. , 1955, The American journal of tropical medicine and hygiene.

[43]  A. Sabin,et al.  PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE , 1945, Science.

[44]  L. Shek,et al.  Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. , 2012, Human vaccines & immunotherapeutics.

[45]  Jorge Arias.  [Dengue in Cuba]. , 2002, Revista panamericana de salud publica = Pan American journal of public health.

[46]  G. Crane.  Dengue haemorrhagic fever: diagnosis, treatment, prevention and control , 1999 .

[47]  A. Sabin.  Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.